[PBBANK] QoQ Annualized Quarter Result on 30-Jun-2019 [#2]

Announcement Date
14-Aug-2019
Admission Sponsor
-
Sponsor
-
Financial Year
31-Dec-2019
Quarter
30-Jun-2019 [#2]
Profit Trend
QoQ- -2.74%
YoY- -2.09%
View:
Show?
Annualized Quarter Result
31/03/20 31/12/19 30/09/19 30/06/19 31/03/19 31/12/18 30/09/18 CAGR
Revenue 22,060,720 22,454,734 22,374,146 22,332,626 22,271,796 22,041,785 21,879,689 0.55%
PBT 6,908,588 7,134,144 7,082,201 7,099,668 7,277,040 7,101,165 7,081,928 -1.63%
Tax -1,540,852 -1,554,701 -1,536,576 -1,538,858 -1,568,204 -1,436,253 -1,428,766 5.15%
NP 5,367,736 5,579,443 5,545,625 5,560,810 5,708,836 5,664,912 5,653,161 -3.39%
-
NP to SH 5,316,304 5,511,558 5,474,254 5,486,078 5,640,372 5,590,611 5,580,340 -3.17%
-
Tax Rate 22.30% 21.79% 21.70% 21.68% 21.55% 20.23% 20.17% -
Total Cost 16,692,984 16,875,291 16,828,521 16,771,816 16,562,960 16,376,873 16,226,528 1.90%
-
Net Worth 43,266,818 43,594,471 42,604,914 42,408,478 40,976,745 40,972,865 39,800,070 5.72%
Dividend
31/03/20 31/12/19 30/09/19 30/06/19 31/03/19 31/12/18 30/09/18 CAGR
Div - 2,833,960 1,708,140 2,562,211 - 2,678,675 1,656,379 -
Div Payout % - 51.42% 31.20% 46.70% - 47.91% 29.68% -
Equity
31/03/20 31/12/19 30/09/19 30/06/19 31/03/19 31/12/18 30/09/18 CAGR
Net Worth 43,266,818 43,594,471 42,604,914 42,408,478 40,976,745 40,972,865 39,800,070 5.72%
NOSH 3,882,138 3,882,138 3,882,138 3,882,138 3,882,138 3,882,138 3,882,138 0.00%
Ratio Analysis
31/03/20 31/12/19 30/09/19 30/06/19 31/03/19 31/12/18 30/09/18 CAGR
NP Margin 24.33% 24.85% 24.79% 24.90% 25.63% 25.70% 25.84% -
ROE 12.29% 12.64% 12.85% 12.94% 13.76% 13.64% 14.02% -
Per Share
31/03/20 31/12/19 30/09/19 30/06/19 31/03/19 31/12/18 30/09/18 CAGR
RPS 568.26 578.41 576.34 575.27 573.70 567.77 563.60 0.54%
EPS 136.96 141.97 141.01 141.32 145.28 144.37 144.23 -3.38%
DPS 0.00 73.00 44.00 66.00 0.00 69.00 42.67 -
NAPS 11.1451 11.2295 10.9746 10.924 10.5552 10.5542 10.2521 5.72%
Adjusted Per Share Value based on latest NOSH - 3,882,138
31/03/20 31/12/19 30/09/19 30/06/19 31/03/19 31/12/18 30/09/18 CAGR
RPS 113.65 115.68 115.27 115.05 114.74 113.55 112.72 0.54%
EPS 27.39 28.39 28.20 28.26 29.06 28.80 28.75 -3.17%
DPS 0.00 14.60 8.80 13.20 0.00 13.80 8.53 -
NAPS 2.229 2.2459 2.1949 2.1848 2.111 2.1108 2.0504 5.72%
Price Multiplier on Financial Quarter End Date
31/03/20 31/12/19 30/09/19 30/06/19 31/03/19 31/12/18 30/09/18 CAGR
Date 31/03/20 31/12/19 30/09/19 28/06/19 29/03/19 31/12/18 28/09/18 -
Price 15.90 19.44 20.08 23.00 23.16 24.76 25.00 -
P/RPS 2.80 3.36 3.48 4.00 4.04 4.36 4.44 -26.44%
P/EPS 11.61 13.69 14.24 16.28 15.94 17.19 17.39 -23.59%
EY 8.61 7.30 7.02 6.14 6.27 5.82 5.75 30.85%
DY 0.00 3.76 2.19 2.87 0.00 2.79 1.71 -
P/NAPS 1.43 1.73 1.83 2.11 2.19 2.35 2.44 -29.94%
Price Multiplier on Announcement Date
31/03/20 31/12/19 30/09/19 30/06/19 31/03/19 31/12/18 30/09/18 CAGR
Date 22/05/20 26/02/20 07/11/19 14/08/19 29/04/19 20/02/19 25/10/18 -
Price 15.26 17.48 19.86 20.80 22.58 25.06 24.90 -
P/RPS 2.69 3.02 3.45 3.62 3.94 4.41 4.42 -28.16%
P/EPS 11.14 12.31 14.08 14.72 15.54 17.40 17.32 -25.46%
EY 8.97 8.12 7.10 6.79 6.43 5.75 5.77 34.16%
DY 0.00 4.18 2.22 3.17 0.00 2.75 1.71 -
P/NAPS 1.37 1.56 1.81 1.90 2.14 2.37 2.43 -31.73%

PBT = Profit before Tax, NP = Net Profit, NP to SH = Net Profit Attributable to Shareholder, Div = Dividend, NP Margin = Net Profit Margin, ROE = Return on Equity, NOSH = Number of Shares, RPS = Revenue per Share, EPS = Earning Per Share, DPS = Dividend Per Share, NAPS = Net Asset Per Share, EOQ = End of Quarter, ANN = Announcement, P/RPS = Price/Revenue per Share, P/EPS = Price/Earning per Share, P/NAPS = Price/Net Asset per Share, EY = Earning Yield, DY = Dividend Yield.

NOSH is estimated based on the NP to SH and EPS. Div is an estimated figure based on the DPS and NOSH. Net Worth is an estimated figure based on the NAPS and NOSH.

Div Payout %, NP Margin, ROE, DY, QoQ & YoY figures in Percentage; RPS, EPS & DPS's figures in Cent; and NAPS's figures in Dollar.

All figures in '000 unless specified.

Discussions
Be the first to like this. Showing 0 of 0 comments

Post a Comment